Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darifenacin in MS patients with neurogenic detrusor overactivity
NCT00845338Phase 2Terminated
- Sponsor
- Bayer
- Start
- Feb 2007
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of darifenacin in neurogenic detrusor overactivity (NDO), sponsored by Bayer. Started Feb 2007; status: terminated.
02
Drugs
darifenacin
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT00845338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00845338.